Malignant disease | |||||
---|---|---|---|---|---|
Malignant disease / Antibody responsive malignancy | |||||
bevacizumab | Restricted |
NICE TA118 NICE TA212 NICE TA242 NICE TA178 NICE TA214 NICE TA263 NICE TA284 NICE TA285 NICE TA666 NICE TA693 |
|||
brentuximab vedotin | Nice-approved drug |
NICE TA478 NICE TA641 NICE TA524 NICE TA577 |
|||
cetuximab | Restricted |
NICE TA145 NICE TA473 NICE TA242 NICE TA439 NICE TA668 |
|||
ipilimumab | Nice-approved drug |
NICE TA268 NICE TA319 NICE TA400 NICE TA716 NICE TA724 NICE TA780 |
|||
obinutuzumab | Nice-approved drug |
NICE TA343 NICE TA513 NICE TA629 |
|||
panitumumab | Off Formulary |
NICE TA242 NICE TA439 |
|||
polatuzumab vedotin | Restricted |
NICE TA649 |
|||
rituximab | Restricted |
NICE TA308 NICE TA195 NICE TA243 NICE TA137 NICE TA193 NICE TA226 NICE TA174 NICE TA359 NICE TA561 |
|||
trastuzumab | Restricted |
NICE TA34 NICE TA257 NICE TA509 NICE TA208 |
|||
trastuzumab emtansine | Restricted |
NICE TA458 NICE TA632 |
|||
Malignant disease / Immunotherapy responsive malignancy | |||||
Bacillus Calmette-Guérin | Restricted | ||||
interferon gamma-1b | Off Formulary | ||||
lenalidomide | Restricted |
NICE TA322 NICE TA171 NICE TA505 NICE TA586 NICE TA587 NICE TA627 NICE TA680 |
|||
mifamurtide | Nice-approved drug |
NICE TA235 |
|||
pomalidomide | Restricted |
NICE TA427 |
|||
thalidomide | Restricted |
NICE TA228 |
|||
Malignant disease / Targeted therapy responsive malignancy | |||||
afatinib | Nice-approved drug |
NICE TA310 |
|||
aflibercept | Off Formulary |
NICE TA294 NICE TA305 NICE TA346 NICE TA409 NICE TA486 NICE TA307 |
|||
axitinib | Restricted |
NICE TA333 NICE TA645 NICE TA650 |
|||
bortezomib | Restricted |
NICE TA370 NICE TA311 NICE TA228 NICE TA129 |
|||
crizotinib | Restricted |
NICE TA406 NICE TA422 NICE TA529 |
|||
dasatinib | Restricted |
NICE TA426 NICE TA425 |
|||
erlotinib | Restricted |
NICE TA227 NICE TA258 NICE TA374 NICE TA374 |
|||
everolimus | Restricted |
NICE TA421 NICE TA432 NICE TA449 |
|||
Afinitor® NICE TA498 Certican® NICE TA348 Certican® NICE TA481 |
|||||
gefitinib | Restricted |
NICE TA192 NICE TA374 |
|||
idelalisib | Restricted |
NICE TA359 NICE TA604 |
|||
imatinib | Restricted |
NICE TA326 NICE TA70 NICE TA86 NICE TA209 NICE TA426 NICE TA425 |
|||
Tablet | |||||
Imatinib (Non-proprietary) | Restricted | ||||
Glivec (Novartis Pharmaceuticals UK Ltd) | Off Formulary | ||||
ixazomib | Nice-approved drug |
NICE TA505 |
|||
lapatinib | Off Formulary |
NICE TA257 |
|||
nilotinib | Restricted |
NICE TA426 NICE TA425 |
|||
palbociclib | Off Formulary |
NICE TA495 NICE TA619 |
|||
pazopanib | Restricted |
NICE TA215 |
|||
ruxolitinib | Restricted |
NICE TA386 |
|||
sorafenib | Restricted |
NICE TA178 NICE TA474 NICE TA535 |
|||
sunitinib | Restricted |
NICE TA169 NICE TA179 NICE TA178 NICE TA449 |
|||
temsirolimus | Off Formulary |
NICE TA178 |
|||
vandetanib | Off Formulary |
NICE TA550 |
|||
vemurafenib | Nice-approved drug |
NICE TA269 |
|||
Malignant disease / Cytotoxic responsive malignancy | |||||
arsenic trioxide | Off Formulary |
NICE TA526 |
|||
asparaginase | Restricted | ||||
azacitidine | Restricted |
NICE TA399 NICE TA218 |
|||
bendamustine hydrochloride | Restricted |
NICE TA216 NICE TA472 |
|||
bexarotene | Off Formulary | ||||
bleomycin | Restricted | ||||
busulfan | Restricted | ||||
cabazitaxel | Nice-approved drug |
NICE TA391 |
|||
capecitabine | Restricted |
NICE TA263 NICE TA212 NICE TA191 NICE TA61 NICE TA100 |
|||
carboplatin | Restricted |
NICE TA284 NICE TA285 |
|||
Solution for infusion | |||||
Carboplatin (Non-proprietary) | Restricted | ||||
carmustine | Restricted |
NICE TA121 |
|||
chlorambucil | Restricted |
NICE TA343 NICE TA344 |
|||
cisplatin | Restricted | ||||
Solution for infusion | |||||
Cisplatin (Non-proprietary) | Restricted | ||||
cladribine | Restricted |
NICE TA616 |
|||
Solution for infusion | |||||
Leustat (Janssen-Cilag Ltd) | Off Formulary | ||||
clofarabine | Restricted | ||||
crisantaspase | Restricted | ||||
Powder for solution for injection | |||||
Erwinase (Porton Biopharma Ltd) | Off Formulary | ||||
cyclophosphamide | Restricted | ||||
cytarabine | Restricted | ||||
Solution for injection | |||||
Cytarabine (Non-proprietary) | Restricted | ||||
dacarbazine | Restricted | ||||
daunorubicin | Restricted | ||||
decitabine | Off Formulary | ||||
docetaxel | Restricted |
NICE TA101 NICE TA509 |
|||
doxorubicin hydrochloride | Restricted |
NICE TA389 NICE TA465 |
|||
Solution for infusion | |||||
Caelyx (Baxter Healthcare Ltd) | Off Formulary | ||||
epirubicin hydrochloride | Restricted | ||||
estramustine phosphate | Restricted | ||||
etoposide | Restricted | ||||
Capsule | |||||
Vepesid (Neon Healthcare Ltd) | Off Formulary | ||||
Powder for solution for injection | |||||
Etopophos (Neon Healthcare Ltd) | Off Formulary | ||||
Solution for infusion | |||||
Etoposide (Non-proprietary) | Restricted | ||||
fludarabine phosphate | Restricted |
NICE TA119 NICE TA29 |
|||
fluorouracil | Restricted | ||||
gemcitabine | Restricted |
NICE TA25 NICE TA116 NICE TA285 NICE TA389 NICE TA476 |
|||
hydroxycarbamide | Restricted | ||||
Tablet | |||||
Siklos (Masters Pharmaceuticals Ltd) | Off Formulary | ||||
Capsule | |||||
Hydroxycarbamide (Non-proprietary) | Restricted | ||||
Hydrea (Bristol-Myers Squibb Pharmaceuticals Ltd) | Off Formulary | ||||
idarubicin hydrochloride | Restricted | ||||
ifosfamide | Restricted | ||||
Powder for solution for injection | |||||
Ifosfamide (Non-proprietary) | Off Formulary | ||||
irinotecan hydrochloride | Restricted |
NICE TA440 |
|||
Solution for infusion | |||||
Campto (Pfizer Ltd) | Off Formulary | ||||
lomustine | Restricted | ||||
Capsule | |||||
Lomustine (Non-proprietary) | Restricted | ||||
melphalan | Restricted | ||||
mercaptopurine | Restricted | ||||
methotrexate | Restricted | ||||
Solution for injection | |||||
Methotrexate (Non-proprietary) | Restricted | ||||
Metoject PEN (medac UK) | Restricted | ||||
Nordimet (Nordic Pharma Ltd) | Restricted | ||||
mitomycin | Restricted | ||||
Powder for solution for injection | |||||
Mitomycin (Non-proprietary) | Restricted | ||||
mitotane | Off Formulary | ||||
mitoxantrone | Restricted | ||||
Solution for infusion | |||||
Mitoxantrone (Non-proprietary) | Restricted | ||||
nelarabine | Off Formulary | ||||
oxaliplatin | Restricted |
NICE TA100 NICE TA93 |
|||
paclitaxel | Restricted |
NICE TA55 NICE TA284 NICE TA389 NICE TA476 |
|||
Solution for infusion | |||||
Paclitaxel (Non-proprietary) | Restricted | ||||
pemetrexed | Restricted |
NICE TA124 NICE TA181 NICE TA402 NICE TA190 NICE TA135 |
|||
pentostatin | Restricted | ||||
Powder for solution for injection | |||||
Nipent (Pfizer Ltd) | Off Formulary | ||||
pixantrone | Nice-approved drug |
NICE TA306 |
|||
procarbazine | Restricted | ||||
Capsule | |||||
Procarbazine (Non-proprietary) | Restricted | ||||
raltitrexed | Off Formulary | ||||
tegafur with gimeracil and oteracil | Off Formulary | ||||
temozolomide | Restricted |
NICE TA23 NICE TA121 |
|||
Capsule | |||||
Temodal (Merck Sharp & Dohme (UK) Ltd) | Off Formulary | ||||
thiotepa | Off Formulary | ||||
tioguanine | Restricted | ||||
topotecan | Restricted |
NICE TA183 NICE TA184 NICE TA389 |
|||
trabectedin | Nice-approved drug |
NICE TA185 NICE TA389 |
|||
treosulfan | Restricted |
NICE TA640 |
|||
tretinoin | Restricted | ||||
vinblastine sulfate | Restricted | ||||
Solution for injection | |||||
Vinblastine sulfate (Non-proprietary) | Restricted | ||||
vincristine sulfate | Restricted | ||||
Solution for injection | |||||
Vincristine sulfate (Non-proprietary) | Restricted | ||||
vindesine sulfate | Off Formulary | ||||
vinflunine | Off Formulary |
NICE TA272 |
|||
vinorelbine | Restricted | ||||
Malignant disease / Cytotoxic drug-induced side effects | |||||
dexrazoxane | Restricted | ||||
folinic acid | Restricted |
NICE TA212 |
|||
levofolinic acid | Off Formulary | ||||
mesna | Restricted | ||||
Malignant disease / Hyperuricaemia associated with cytotoxic drugs | |||||
rasburicase | Restricted | ||||
Powder and solvent for solution for infusion | |||||
Fasturtec (Sanofi) | Off Formulary | ||||
Malignant disease / Hormone responsive malignancy | |||||
abiraterone acetate | Restricted |
NICE TA259 NICE TA387 NICE TA721 |
|||
bicalutamide | Restricted | ||||
Tablet | |||||
Casodex (AstraZeneca UK Ltd) | Off Formulary | ||||
cyproterone acetate | On Formulary | ||||
Tablet | |||||
Cyproterone acetate (Non-proprietary) | On Formulary | ||||
degarelix | Nice-approved drug |
NICE TA404 |
|||
diethylstilbestrol | Restricted | ||||
Tablet | |||||
Diethylstilbestrol (Non-proprietary) | Restricted | ||||
enzalutamide | Nice-approved drug |
NICE TA316 NICE TA377 NICE TA580 NICE TA712 |
|||
ethinylestradiol | Restricted | ||||
flutamide | Restricted | ||||
Tablet | |||||
Flutamide (Non-proprietary) | Restricted | ||||
goserelin | Restricted | ||||
lanreotide | Restricted | ||||
Solution for injection | |||||
Somatuline Autogel (Ipsen Ltd) | Restricted | ||||
Powder and solvent for suspension for injection | |||||
Somatuline LA (Ipsen Ltd) | Off Formulary | ||||
leuprorelin acetate | Restricted | ||||
medroxyprogesterone acetate | Restricted | ||||
Tablet | |||||
Provera (Pfizer Ltd) | Off Formulary | ||||
megestrol acetate | Restricted | ||||
Tablet | |||||
Megace (Bausch & Lomb UK Ltd) | Off Formulary | ||||
norethisterone | Restricted | ||||
octreotide | Restricted | ||||
Solution for injection | |||||
Sandostatin (Novartis Pharmaceuticals UK Ltd) | Off Formulary | ||||
Powder and solvent for suspension for injection | |||||
Sandostatin LAR (Novartis Pharmaceuticals UK Ltd) | Off Formulary | ||||
triptorelin | Off Formulary | ||||
Malignant disease / Hormone responsive breast cancer | |||||
anastrozole | Restricted | ||||
Tablet | |||||
Arimidex (AstraZeneca UK Ltd) | Off Formulary | ||||
exemestane | Restricted | ||||
Tablet | |||||
Aromasin (Pfizer Ltd) | Off Formulary | ||||
fulvestrant | Off Formulary |
NICE TA503 |
|||
Solution for injection | |||||
Faslodex (AstraZeneca UK Ltd) | Off Formulary | ||||
letrozole | Restricted | ||||
tamoxifen | Restricted | ||||
toremifene | Off Formulary | ||||
Malignant disease / Photodynamic therapy responsive malignancy | |||||
porfimer sodium | Off Formulary | ||||
temoporfin | Off Formulary | ||||
Malignant disease / Secondary bone metastases and hypercalcaemia | |||||
denosumab | Nice-approved drug |
NICE TA204 NICE TA265 |
|||
ibandronic acid | Restricted |
NICE TA464 |
|||
pamidronate disodium | On Formulary | ||||
sodium clodronate | On Formulary | ||||
zoledronic acid | Restricted |
NICE TA464 |
|||
Infusion | |||||
Aclasta (Novartis Pharmaceuticals UK Ltd) | Off Formulary |